FAM149B1 Inhibitors
Chemical inhibitors of FAM149B1 can operate through various modes of action, primarily by targeting and impeding specific cellular pathways that are crucial for cell cycle progression and proliferation. CDK4/6 inhibitors such as Palbociclib, Ribociclib, and Abemaciclib can inhibit FAM149B1 by arresting the cell cycle in the G1 phase. This blockade can lead to a reduction in the activity of proteins that are critical for the transition from the G1 phase to the S phase of the cell cycle, where DNA replication occurs. These inhibitors act by preventing the phosphorylation of retinoblastoma protein (pRb), which in turn halts the activity of E2F transcription factors that are essential for advancing the cell cycle, thereby influencing the activity of FAM149B1 if it is implicated in this process.
In addition to CDK4/6 inhibitors, MEK inhibitors such as Trametinib, Cobimetinib, and Selumetinib can inhibit FAM149B1 by interfering with the MEK/ERK pathway. This pathway is instrumental in cell growth and differentiation, and its disruption can affect the function of various proteins engaged in these processes. Similarly, BRAF inhibitors like Dabrafenib, Vemurafenib, and Encorafenib can inhibit FAM149B1 by targeting the BRAF kinase, particularly those with the V600E mutation, thereby affecting the downstream MEK/ERK signaling pathway. This action can alter the function of proteins associated with the pathway, which may include FAM149B1 if it is involved in these signaling cascades. Lastly, EGFR inhibitors such as Gefitinib, Erlotinib, and Lapatinib inhibit FAM149B1 by blocking the EGFR signaling pathway. By inhibiting the tyrosine kinase activity of EGFR, these inhibitors can reduce the signaling through pathways that are critical for the regulation of cell proliferation and survival, which in turn can have an impact on the activity of FAM149B1.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
Palbociclib is a CDK4/6 inhibitor that could inhibit FAM149B1 by halting the cell cycle in the G1 phase, which may lead to reduced activity of proteins involved in cell cycle progression, potentially including FAM149B1. | ||||||
Ribociclib | 1211441-98-3 | sc-507367 | 10 mg | $450.00 | ||
Ribociclib serves as a CDK4/6 inhibitor, potentially leading to decreased phosphorylation of proteins associated with the cell cycle, and could thereby inhibit the activity of FAM149B1 if it is involved in cell proliferation. | ||||||
Abemaciclib | 1231929-97-7 | sc-507342 | 10 mg | $110.00 | ||
Abemaciclib, another CDK4/6 inhibitor, could inhibit FAM149B1 by impeding cell cycle progression and thus potentially impacting the activity of proteins that play a role in cell division. | ||||||
Trametinib | 871700-17-3 | sc-364639 sc-364639A sc-364639B | 5 mg 10 mg 1 g | $114.00 $166.00 $947.00 | 19 | |
Trametinib is a MEK inhibitor that could inhibit FAM149B1 by interfering with the MEK/ERK pathway, which is implicated in cell growth and differentiation, potentially impacting proteins involved in these processes. | ||||||
Cobimetinib | 934660-93-2 | sc-507421 | 5 mg | $270.00 | ||
Cobimetinib targets MEK1/2 in the MAPK pathway, potentially inhibiting FAM149B1 by reducing the activity of this pathway, which could affect proteins associated with cellular differentiation and proliferation. | ||||||
Selumetinib | 606143-52-6 | sc-364613 sc-364613A sc-364613B sc-364613C sc-364613D | 5 mg 10 mg 100 mg 500 mg 1 g | $29.00 $82.00 $420.00 $1897.00 $3021.00 | 5 | |
Selumetinib is a MEK inhibitor that could inhibit FAM149B1 by attenuating the downstream signaling of MEK, potentially impacting the activity of proteins associated with cell cycle regulation and growth. | ||||||
Dabrafenib | 1195765-45-7 | sc-364477 sc-364477A sc-364477B sc-364477C sc-364477D | 5 mg 25 mg 50 mg 100 mg 10 g | $141.00 $260.00 $278.00 $411.00 $12485.00 | 6 | |
Dabrafenib is a BRAF inhibitor that could inhibit FAM149B1 indirectly by inhibiting the BRAF/MEK/ERK pathway, potentially affecting the function of proteins linked to this pathway and cell proliferation. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib selectively inhibits BRAF kinases with the V600E mutation, which could inhibit FAM149B1 by impacting downstream signaling pathways associated with cell growth and division. | ||||||
Encorafenib | 1269440-17-6 | sc-507422 | 1 mg | $115.00 | ||
Encorafenib is a BRAF inhibitor that could inhibit FAM149B1 by diminishing the signaling through BRAF/MEK/ERK pathway, potentially affecting proteins that influence cell cycle and growth. | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is an EGFR inhibitor which could inhibit FAM149B1 by blocking the EGFR signaling pathway, possibly leading to reduced activity of proteins that are regulated by this pathway and are involved in cell proliferation. | ||||||